The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study examining the potential of XPro™ to slow cognitive decline in early-stage Alzheimer’s disease (AD) by targeting neuroinflammation.

No one can live without a heart pumping blood to the rest of the body. New research from the University of Missouri School of ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...